Overview
- Pfizer declared a $0.43 quarterly dividend, its 350th straight payment, with the stock now yielding about 6.4% by recent quotes.
- Management guided for 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3.00 per share.
- The company said sales from COVID products should decline this year while non‑COVID medicines hold steady.
- Shares have dropped more than 30% over five years as investors question how fast growth can recover.
- CEO Albert Bourla is leaning on acquisitions and in‑house R&D to add about $25 billion in annual sales by decade‑end, pointing to a pipeline with more than 100 drug candidates.